Neratinib maleate (HKI-272 maleate) | HER2/EGFR Inhibitor | MedChemExpress
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Nerlynx (neratinib) Cancer Medication - Cancer Health
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Puma Biotechnology Surging
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Mechanism of action | NERLYNX® (neratinib) tablets
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Buy Nerlynx (neratinib) Online • Price & Costs | Everyone.org
Neratinib | 99.94%(HPLC) | In Stock | HER2 inhibitor
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer - ScienceDirect
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Puma Bio FDA Advisory Panel Live Blog - TheStreet
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | BioSpace
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Neratinib | C30H29ClN6O3 | CID 9915743 - PubChem
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Puma Biotechnology expands deal with Pierre Fabre to include additiona
Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia | Future Oncology
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Neratinib - Wikipedia
Neratinib for breast cancer – the key is managing gastrointestinal toxicity | Cancer Biology
pbyi20211231_10k.htm
